Medicare Part D: The cost of ending drug subsidies
The Trump administration will end a Biden-era Medicare Part D subsidy for drug-plan insurers starting next year, according to The Wall Street Journal. The program provides about $3.6 billion this year to reduce premium increases. Average premiums fell about 40% in 2025 for 25 million enrollees, but about 75% could pay more by 2027. CMS says the insurer “bailout” is unnecessary; Oz cited UnitedHealth Group as receiving over half the funds.
How this was made
The 30-second read
Why it matters
Ending the subsidy shifts costs from the government to enrollees and taxpayers, and the article highlights that insurers raised rates expecting government support. It also notes the program reduced average premiums by about 40% in 2025, implying a likely premium reset in 2027 after cancellation.
Market read
Policy-driven change to Medicare Part D subsidy economics is a tangible earnings risk for major Medicare insurers, especially those cited as large subsidy recipients.
What to watch
The article does not quantify UNH’s contract-level exposure, whether CMS will offset via other mechanisms, or how pharma cost-lowering efforts could partially offset premium pressure.
Background
The piece describes a Biden-era Part D subsidy program that began in 2024 and was intended to blunt premium increases for Medicare drug plans.
Ticker impact
The article says more than half of the Part D subsidy money flowed to UnitedHealth Group, calling it unacceptable and implying direct financial impact.
Moderate downside risk to UNH estimates and near-term sentiment, with details likely to be clarified by CMS/insurer filings.
The text attributes a large share of subsidy dollars to UNH and frames the cancellation as a policy shift, which can change premium/contract economics and cost-to-serve assumptions.
Market effects
Medicare Advantage and Part D insurers face higher premium volatility and potentially lower margin support if subsidies were propping up rate increases.
Primarily US healthcare policy impact; limited direct non-US spillover.
US policy-driven read-through to global managed-care sentiment, but effects are mostly domestic.
Counterpoint
Insurers may have already priced in the subsidy’s temporary nature, so the incremental impact could be smaller than implied by the subsidy share.
Key entities
- companyUnitedHealth Group
Named as receiving more than half of the Part D subsidy money, making it a direct beneficiary of the policy being removed.
- government_agencyCenters for Medicare and Medicaid Services (CMS)
Referenced via administrator Mehmet Oz, who criticized the subsidy as an insurer bailout.
- programMedicare Part D
Medicare prescription drug coverage program whose insurer premium economics are affected by the subsidy cancellation.
